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The importance of the HLA-DR locus to multiple sclerosis (MS) susceptibility was assessed in 542 sib pairs with
MS and in their families. By genotyping 1,978 individuals for HLA-DRB1 alleles, we confirmed the well-established
association of MS with HLA-DRB1*15 (HLA-DRB1*1501 and HLA-DRB5*0101), by the transmission/disequi-
librium test ( ; ). We obtained significant evidence of linkage throughout the whole data set2x p 138.3 P ! .0001
( ; 59.9% sharing). Surprisingly, similar sharing was also observed in 58 families in which both parentsmlodp 4.09
lacked the DRB1*15 allele ( ; 62.7% sharing; ). Our findings suggest that the notion thatmlodp 1.56 Pp .0081
HLA-DRB1*15 is the sole major-histocompatibility-complex determinant of susceptibility in northern-European
populations with MS may be incorrect. It remains possible that the association of MS with HLA-DRB1*15 is due
to linkage disequilibrium with a nearby locus and/or to the presence of disease-influencing allele(s) in DRB1*15-
negative haplotypes.
Studies of twins and of recurrence rates in families have
shown that the risk for multiple sclerosis (MS [MIM
142860]), an inflammatory disease of the CNS, is ge-
netically influenced (Dyment et al. 1997; for review,
see Sadovnick et al. 1997). A large number of studies
have confirmed the association of MS with a haplo-
type carrying the major histocompatibility complex
(MHC) class II HLA-DR15 and HLA-DQ6 alleles (HLA-
DRB1*1501, HLA-DRB5*0101, HLA-DQA1*0102,
and HLA-DQB1*0602). However, since the original
report, ∼26 years ago, of an MHC class II association
(Winchester et al. 1975), the finding has contributed
relatively little to the understanding of disease mech-
anisms (Olerup and Hillert 1991).
Association analysis of HLA genes is complicated by
the presence of many highly polymorphic genes and by
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strong linkage disequilibrium, thus requiring large num-
bers of individuals. Recently, a case-control analysis of
948 Swedish patients withMS confirmed the importance
that DRB1*15 has for susceptibility to MS but showed
no influence on either disease course or disease severi-
ty (Masterman et al. 2000). Because the frequency of
DRB1*15-negative families is relatively low, it has not
previously been possible to adequately evaluate evidence
of linkage in DRB1*15-negative families with MS. The
intent of this study was to extend the analysis to a large
number of families with MS, thereby providing an op-
portunity to assess the influence, independent from the
already-well-established DRB1*15 association, of the
HLA gene region.
The total study group was composed of 441 white
Canadian families—comprising 542 sib pairs with MS.
The types and quantity of families and individuals stud-
ied are shown in table 1. Patients with MS who were
studied herein met the criteria for “clinically probable”
or “clinically definite” MS (Sadovnick et al. 1998). Of
the probands, 88% had clinically definite MS, and 12%
had clinically probable MS. Of the affected siblings,
90.5% were clinically definite, and 9.5% were clinically
probable. Patients who had a relapsing/remitting onset
and patients who had a primary progressive onset were
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Table 1
Details of Families and Individuals Studied
Group No.
Families:
Affected sib pairs 399
Affected trios 39
Four affected individuals 1
Five affected individuals 2
Total 441
Affected sib pairs 542
Families with two parents available 162
Families with one parent available 144
Families with neither parent available 135
Unaffected sib pairs (families) 569 (244)
Individuals 1,978
Table 2
Sharing of HLA-DRB1 Alleles in Siblings with MS, Determined by IBD Analysis or IBS Analysis
Analysis Families Sib Pairs
Sharing
(%) 2x z0 z1 z2 llocus mlod
IBD:
DRB1*15 positive 167 204 59.0 11.58 .17 .48 .35 1.47 2.54
DRB1*15 negative 58 63 62.7 7.00 .14 .47 .39 1.78 1.56
Total 441 542 59.9 18.56 .16 .36 .36 1.56 4.09
IBS:
DRB1*15 positive 58.9 .36 .17 .48 .35 … 2.53
DRB1*15 negative 62.1 2.95 .14 .47 .39 … 1.48
Total 57.0 10.39 .18 .49 .32 … 3.65
NOTE.—Families are subdivided according to presence or absence, in parents, of the MS-associated
allele DRB1*15; only families in which both parents were available were stratified in this way. z values
indicate the most likely frequencies of sharing zero, one, or two chromosomes. Statistical analyses were
performed by the ASPEX-2.3 program.
included in this sample. A natural history study of a
Canadian population with MS provided support for the
notion that these two clinical types of MS share a com-
mon genetic background (Ebers et al. 2000). Genotyping
ofHLA-DRB1 andHLA-DRB5 was performed by PCR
with sequence-specific primers (Olerup SSP AB) in a
nested fashion, with PCR preamplification of a 270-bp
fragment of the DRB genes. The analysis consisted of
24 parallel amplifications with unique primer pairs and
with internal amplification controls for each reaction.
Identity-by-descent (IBD) sharing and identity-by-
state (IBS) sharing were assessed by the sib_ibd and
sib_phase programs of the ASPEX-2.3 statistical pack-
age, respectively. Allele frequencies were estimated from
parental alleles that were not transmitted to affected in-
dividuals (Terwilliger and Ott 1992; Risch and Teng
1998). IBS analysis was performed, as well as IBD anal-
ysis, because IBS analysis uses information from families
in which parental genotypes are unavailable (see table
1). Transmission/disequilibrium testing (TDT) was per-
formed by the sib_tdt program of ASPEX-2.3. Unaf-
fected siblings were included to reconstruct missing pa-
rental information. TDT was performed only in families
that were fully informative, by either genotyping or ge-
notype reconstruction.
Themlod ofDRB1 for the entire data set of 441 families
was 4.09, with 59.9% sharing and (tablePp .000017
2). In addition, 58 families in which neither parent carried
the DRB1*15-susceptibility allele were identified. In the
DRB1*15-negative subset of families, borderline evidence
of linkage was observed ( ; 62.7% sharing;mlodp 1.56
) (table 2).Pp .0081
We then investigated the transmission of DRB1 alleles
to those individuals in the total study group who were
affected (table 3). This confirmed the importance of
DRB1*15 (69% rate of transmission to affected indi-
viduals, ; ). The transmission of2x p 138.3 P ! .00001
DRB1*15 was also assessed in the unaffected offspring.
In this sample, DRB1*15 was transmitted 140 times and
was not transmitted 147 times ( ; P value was2x p 0.13
not significant). The lack of a significant DRB1*1501
transmission deficit in this group may be explained by
the low relative risk of DRB1*1501. All other alleles
also showed a lack of distortion in transmission to un-
affected siblings (data not shown).
To determine whether other DRB1 alleles influence
risk, we reanalyzed the data in table 3, after removing
DRB1*15 (table 4), and also examined the results of a
TDT of the 58 families in which neither parent carries
DRB1*15 (table 5). To do so, we calculated odds ratios
(ORs) for each allele versus all other alleles and tested
the significance of deviation from an OR of 1.0, by a
likelihood-ratio x2 test for the derived table. The2# 2
ORs are given in tables 4 and 5. From the total study
group, it is clear that, in frequency among patients, some
alleles are increased and others are decreased; specifi-
cally, DRB1*14 and DRB1*11 are decreased (i.e., pro-
tective), whereas DRB1*8 is increased. The uncorrected
P value for DRB1*14 is .00355, which, after a conser-
vative (Bonferroni) correction for 13 tests, yields a cor-
rected P value of !.05. When this allele is removed from
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Table 3
Transmission of DRB1 Alleles, in Total Study
Group
Allele T:NTa 2x
bPuncorrected
1 83:134 11.9 .00057
4 128:136 .24 NS
7 111:139 3.14 NS
8 37:26 5.41 .02
9 8:17 6.00 .0143
10 5:5 .09 NS
11 51:91 4.25 .0392
12 8:19 2.29 NS
13 118:126 .68 NS
14 13:39 8.0 .0047
15 330:148 138.3 !.00001
16 13:17 .31 NS
17 114:120 4.84 .0278
18 1:3 .14 NS
NOTE.—Analysis is of HLA-DRB1 alleles
HLA-DRB1*1–HLA-DRB1*18. HLA-DRB1*15
and HLA-DRB1*16 are splits of DR2, whereas
HLA-DRB1*17 andHLA-DRB1*18 are splits of
DR3.
a T p transmitted; NT p not transmitted.
b NS p not significant.
Table 4
Reanalysis of Total Study Group, after Removal
of DRB1*15
Allele T:NT OR 2x Puncorrected
1 83:134 .75 3.62 NS
4 128:136 1.23 2.38 NS
7 111:139 1.01 .01 NS
8 37:26 1.84 5.59 .18
9 8:17 .59 1.57 NS
10 5:5 1.27 .14 NS
11 51:91 .68 4.39 .036
12 8:19 .53 2.45 NS
13 118:126 1.22 2.05 NS
14 13:39 .41 8.50 .00355
15 … … … …
16 13:17 .97 .01 NS
17 114:120 1.24 2.29 NS
18 1:3 .42 .63 NS
NOTE.—Data are as described in the footnotes
to table 3.
analysis and after correction for multiple testing, none
of the alleles are formally significant; however, it is likely
that the predispositional effect of DRB1*8 and the pro-
tective effect of DRB1*11 are also present, given the
similar ORs obtained both in the total study group and
in the DRB1*15-negative families (tables 4 and 5). We
calculated the correlation, in ORs, between the two
groups of families (after excluding DRB1*10 and
DRB1*18, which were observed fewer than five times
in the DRB1*15-negative families). For the remaining
11 ORs, the correlation was .79. Thus, it is possible that
alleles other than DRB1*15 confer different risks, albeit
not as deviant—except, possibly, for DRB1*14, which
appears to have an OR of 1.40—as those conferred by
DRB1*15, which had an OR of 2.23. Furthermore,
DRB1*17, the common split of DR3, which has occa-
sionally been reported to be increased in patients with
MS (Olerup and Hillert 1991; Masterman et al. 2000),
also was increased in our TDT (tables 4 and 5); however,
the ORs were not extremely elevated (e.g., 1.24 and 1.42
in the families in tables 4 and 5, respectively).
From the OR estimates (for DRB1*15 and for other
alleles), it is possible to predict the amount of allele shar-
ing expected in affected sib pairs (Risch 1987). Assuming
a multiplicative model for DRB1*15, an OR of 2.23,
and an allele frequency of .15, we calculated an expected
HLA-allele sharing, across all families, of 53.2%. In-
cluding the other alleles increased the expected sharing
only marginally and, in fact, in DRB1*15-negative fam-
ilies, did not predict allele sharing much in excess of
50%. Thus, it appears that the excess allele sharing of
62.7% in DRB1*15-negative families cannot be ac-
counted for by predispositional or protective effects of
other DRB1 alleles. It appears more likely that another
locus, possibly in linkage disequilibrium with DRB1, is
involved.
Our discovery of linkage in DRB1*15-negative fam-
ilies contrasts with data reported by Haines et al.
(1998). In their study of an American population, ev-
idence of linkage was obtained in families containing
parental DRB1*15-bearing (i.e., DRB1*15-positive)
chromosomes, whereas the non–DR1*15-bearing (i.e.,
DRB1*15-negative) families showed little to no evi-
dence of linkage. However, the DRB1*15-negative
families were few ( ). In addition, several ex-np 19
tended pedigrees were included, increasing the likeli-
hood, owing to genetic heterogeneity, that a few
DRB1*15-negative families strongly influenced the out-
come. It is possible that large extended pedigrees may
differ from sib pairs’ families, and results of compar-
isons therefore should be interpreted with caution.
Using the equation (Risch 1987) and as-z p 0.25/l0 S
suming zero recombination between HLA and MS sus-
ceptibility, we obtained a DRB1-specific of 1.56, inlS
all families. This clearly supports the hypothesis that the
HLA region confers a minority of the genetic etiology
in MS (14.8%; range 7%–34.3% given a LOD-score
interval of 1), since the overall is suggested to be ∼20lS
(Sadovnick et al. 1997). The similarity between the lS
observed in DRB1*15-positive families ( ) andl p 1.56S
that observed in DRB1*15-negative families ( )l p 1.78S
indicates a similar strength of effect (table 2).
In conclusion, we have found evidence of linkage to
the MHC, in the absence of DRB1*15, as well as evi-
dence that the 62.7% sharing observed cannot be ac-
counted for by secondary DRB1 associations (e.g.,
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Table 5
Transmission of DRB1 Alleles, in Affected
Offspring in DRB1*15-Negative Families
Allele T:NT OR 2x Puncorrected
1 34:34 1.00 .00 NS
4 36:37 .97 .02 NS
7 33:27 1.26 .70 NS
8 9:7 1.30 .26 NS
9 2:4 .50 .69 NS
10 3:1 3.03 1.06 NS
11 9:21 .40 5.30 .021
12 5:10 .49 1.76 NS
13 42:29 1.56 2.88 NS
14 1:7 .14 5.15 .024
15 … … … …
16 3:5 .59 .52 NS
17 34:27 1.42 .94 NS
18 0:2 .00 2.78 NS
NOTE.—Data are as described in the footnotes
to table 3.
DRB1*17, DRB1*8, DRB1*14, and DRB1*11). This is
compatible with the presence of either a second locus,
within the HLA region, independent of DR15,DQ6 and
acting to increase MS risk or a single, as-yet-unidentified
primary (i.e., non-DRB1) MS-susceptibility locus in very
strong disequilibrium with the DR15-DQ6 haplotype.
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